Podcast | Terugblik op ASCO 2023: mammacarcinoom

Een van de hoofdonderzoekers van de Nederlandse SONIA studie dr. Agnes Jager gaat in deze podcast in gesprek met dr. Willemien Menke - van der Houven van Oordt. Beide internist-oncologen staan stil bij de highlights op het gebied van mammacarcinoom die tijdens de ASCO op 2 t/m 6 juni 2023 werden gepresenteerd in Chicago. Willemien en Agnes gaan in gesprek over de meest opvallende ontwikkelingen en spraakmakende resultaten op het gebied van vroegstadium en gemetastaseerd mammacarcinoom, waaronder de SONIA en NATALEE studie.

De volgende abstracts komen aan bod:

Vroegstadium mammacarcinoom  

• Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.

• 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).

• Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.

• Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.

Gemetastaseerd mammacarcinoom 

• Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

• Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).

• CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.

• A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).